Tiny URL Website

Monitoring for minimal residual illness and recurrent malignancy will vary according to the particular disease and enrollment in particular protocols. Oral dissolution brokers (ursodeoxycholic acid) partially or com pletely dissolve small radiolucent stones in 50% of selected pts inside 6–24 month...